Izadiyan Zahra, Webster Thomas J, Kia Pooneh, Kalantari Katayoon, Misran Misni, Rasouli Elisa, Maghareh Esfahan Zahra, Shameli Kamyar
Department of Chemistry, Universiti Malaya, Kuala Lumpur, Malaysia.
School of Biomedical Engineering and Health Sciences, Hebei University of Technology, Tianjin, People's Republic of China.
Int J Nanomedicine. 2025 May 14;20:6133-6162. doi: 10.2147/IJN.S488545. eCollection 2025.
Nanoemulsions (NEs), colloidal systems of nanoscale droplets (~100 nm), have emerged as transformative tools in oncology due to their high surface area-to-volume ratio, tunable physicochemical properties, and capacity for targeted drug delivery. While NEs find applications across diverse fields, their urgency in breast cancer therapy stems from critical limitations of conventional treatments, including systemic toxicity, poor bioavailability, and multidrug resistance. Unlike traditional chemotherapeutics, NEs enable precise tumor targeting via passive mechanisms (eg, enhanced permeability and retention effect) and active strategies (eg, ligand-functionalized surfaces), significantly reducing off-target effects. Their ability to encapsulate hydrophobic drugs, improve solubility, and sustain controlled release enhances therapeutic efficacy while overcoming resistance mechanisms prevalent in aggressive breast cancer subtypes, such as triple-negative and HER2-positive tumors. This review comprehensively analyzes NE formulation techniques (eg, ultrasonication, phase inversion temperature, bubble bursting), stability optimization through surfactant dynamics, and predictive modeling of droplet behavior. A focal point is their role in modulating tumor microenvironments, inducing apoptosis, and inhibiting angiogenesis in preclinical breast cancer models. By spotlighting NE-driven advancements in drug accumulation, reduced relapse rates, and adaptable combination therapies, this article underscores their potential to revolutionize oncology. Future research must prioritize clinical translation, scalability, and multifunctional NE designs to address unmet needs in precision breast cancer treatment.
纳米乳剂(NEs)是纳米级液滴(约100纳米)的胶体系统,由于其高的表面积与体积比、可调节的物理化学性质以及靶向药物递送能力,已成为肿瘤学领域变革性工具。虽然纳米乳剂在多个领域有应用,但其在乳腺癌治疗中的紧迫性源于传统治疗的关键局限性,包括全身毒性、低生物利用度和多药耐药性。与传统化疗药物不同,纳米乳剂可通过被动机制(如增强渗透和滞留效应)和主动策略(如配体功能化表面)实现精确的肿瘤靶向,显著减少脱靶效应。它们封装疏水药物、提高溶解度和维持控释的能力增强了治疗效果,同时克服了侵袭性乳腺癌亚型(如三阴性和HER2阳性肿瘤)中普遍存在的耐药机制。本综述全面分析了纳米乳剂的制备技术(如超声处理、相转变温度、气泡破裂)、通过表面活性剂动力学优化稳定性以及液滴行为的预测建模。重点是它们在临床前乳腺癌模型中调节肿瘤微环境、诱导细胞凋亡和抑制血管生成方面的作用。通过突出纳米乳剂在药物蓄积、降低复发率和适应性联合治疗方面的进展,本文强调了它们在肿瘤学领域引发变革的潜力。未来研究必须优先考虑临床转化、可扩展性和多功能纳米乳剂设计,以满足精准乳腺癌治疗中未满足的需求。